CELC vs PFE
CELC: Celcuity is developing gedatolisib, a comprehensive PI3K/AKT/mTOR pathway inhibitor in Phase 3 trials for hormone receptor-positive breast cancer and metastatic prostate cancer. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | CELC | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $90.14 | $24.82 | |
| Market cap as of 2026-07-23 | $4.4B | $142.0B | |
| P/E as of 2026-07-23 | n/a | 18.96 | |
| PEG as of 2026-07-23 | -0.82 | -3.38 | PFE lower |
| Net margin as of 2026-07-23 | n/a | +11.8% | |
| Gross margin as of 2026-07-23 | n/a | +74.8% | |
| Operating margin as of 2026-07-23 | n/a | +15.4% | |
| ROE as of 2026-07-23 | -244.6% | +8.4% | PFE higher |
| ROA as of 2026-07-23 | -50.2% | +3.6% | PFE higher |
| Debt / equity as of 2026-07-23 | 6.04 | 0.72 | PFE lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +1.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.8% | |
| Dividend yield as of 2026-07-23 | n/a | +6.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.20 | 0.28 | |
| 1-year return as of 2026-07-22 close | +546.6% | -1.3% | CELC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.